Suven ended at its 10% upper circuit limit at Rs 15.85. The stock clocked a volume of 271,381 shares on the BSE.
Updated at 1220 hrs
Suven Life Sciences has soared to its upper circuit following news of the US FDA giving its approval to their intermediate pharmaceutical ingredient facility in Andhra Pradesh.
This is Suven's second facility to get the US FDA's nod. The US FDA has classified Suven facility as acceptable for manufacture and supply of intermediates for active pharmaceutical ingredients.
The stock opened at Rs 15 and dropped to a low of Rs 14.51. It soon zoomed 10% to reach its upper limit at Rs 15.85. A total of 133,326 shares have been traded on the BSE so far. Buy orders for over 34,000 shares are still pending at the counter.
Content Guide
